Cardinal Health, Inc. (CAH)
NYSE · Dublin, Ohio, USA · Founded 1971 · CEO Jason Hollar
Valuation summary
$166.66 fair value versus $272.34 in the market, a difference of -38.8%. Rated Sell.
| Fair value per share | $166.66 |
| Current share price | $272.34 |
| Upside / downside | -38.8% |
| Bear case | N/M |
| Bull case | $923.36 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.60% |
| Market capitalisation | $63B |
| EV / Sales | 0.3x |
About Cardinal Health, Inc.
Founded in 1971 by Robert Walter as a food wholesaler, Cardinal moved into drug distribution in 1979. Jason Hollar has been chief executive since 2022. It is one of the three companies, with McKesson and Cencora, that deliver most prescription medicines to US pharmacies and hospitals; it also makes and distributes medical products such as gloves and gowns. Revenue is enormous but profit margins are around 1%, so small changes matter.
Investment case
- Specialty medicines, the fastest-growing part of pharmacy, are an expanding share of its business.
- Three distributors control the market, which keeps competition orderly.
- Earnings have beaten expectations repeatedly under current management.
Key risks
- Margins are wafer-thin and depend on generic drug pricing.
- Losing a large customer contract can remove a big slice of revenue.
- Drug pricing policy in Washington is a constant uncertainty.
Revenue by segment
| Pharmaceutical and Specialty Solutions | 92% |
| Medical Products and Distribution | 5% |
| Other businesses | 3% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $281.8B | $1.1B |
| Year 2 | $309.6B | $1.4B |
| Year 3 | $339.5B | $1.8B |
| Year 4 | $371.9B | $2.3B |
| Year 5 | $406.8B | $2.9B |
What the street says
A turnaround that worked; now valued closer to its two larger peers.
Comparable companies: MCK · COR · MDLN · HUM · CI · BSX · DXCM · ELV
Open the interactive model, price chart and sensitivity grid →